Local Anesthesia For Ophthalmologic Procedure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for local anesthesia for ophthalmologic procedure. 112 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
112
Active US patents
68/100
Avg vulnerability
—
Annual revenue covered

Originators in Local Anesthesia For Ophthalmologic Procedure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Innocoll 108 patents Fresenius Kabi 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating local anesthesia for ophthalmologic procedure. Each bar = one year. Y-axis scaled to peak year (42 patents).

1
26
1
29
20
34
42
35
4
36
30
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Bupivacaine Hydrochloride And Epinephrine
BUPIVACAINE
 Innocoll 108 64 — 2034-03-13
Lignospan Forte
Lidocaine Hydrochloride
 Fresenius Kabi 4 71 — 2026-07-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759401 Lignospan Forte method of use 85 2026-07-24
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
12144890 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
11925706 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12151024 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12296047 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12296047 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20
10398686 Bupivacaine Hydrochloride And Epinephrine formulation 42 2034-03-13
9744163 Bupivacaine Hydrochloride And Epinephrine formulation 42 2034-03-13
9744163 Bupivacaine Hydrochloride And Epinephrine formulation 42 2034-03-13
9744163 Bupivacaine Hydrochloride And Epinephrine formulation 42 2034-03-13
10398686 Bupivacaine Hydrochloride And Epinephrine formulation 42 2034-03-13
9744163 Bupivacaine Hydrochloride And Epinephrine formulation 42 2034-03-13

Related